iRhythm Supports Cardiac Patients During the COVID-19 Crisis, While Keeping Clinicians Safe, Through Zio Virtual Platform
- Zio virtual platform reduces COVID-19 spread by monitoring higher risk patients at home
- New program with severely ill COVID-19 patients rolled out at three
New York Cityhospitals within Montefiore Health System
iRhythm is providing Zio AT mobile cardiac telemetry solutions to monitor the near real-time heart health of severely ill COVID-19 patients, providing a multi-campus solution for
“Early in the outbreak of this pandemic, we recognized a need to deploy existing technologies to provide better care to our COVID-19 patients at risk for cardiac complications who were being housed on numerous units across three campuses. These patients require both inpatient and outpatient monitoring because we still don’t know the extent to which they’re at risk for additional cardiac problems. In addition to being able to more closely monitor our patients, clinicians and nurses are in the hospital room with COVID-19 patients for up to 10 minutes, twice daily, to monitor them with a 12-lead ECG; now, we’re in the room once and for roughly five minutes, without compromising the care provided to the patient. Zio’s heart monitoring solution is making a real difference in not only our patients’ health, but also in the health of our staffers by limiting our exposure to this virus,” said
COVID-19 has been associated with cardiac effects such as atrial fibrillation, ventricular arrhythmias, ventricular ectopy, and torsades de pointe (TdP). For patients with underlying heart conditions, COVID-19 can have fatal consequences. In addition, some medications may lead to QT prolongation as a side effect, causing the heart muscle to take longer than normal to recharge between beats. Monitoring of this electrical disturbance is typically performed by a 12-lead electrocardiogram (ECG), exposing nurses and ECG technicians to multiple points of contact with COVID-19 patients each day, or by using high-demand telemetry beds.
Meanwhile, patients with heart conditions are at high risk for complications if they get the virus. Home enrollment with Zio XT and Zio AT devices allows clinicians to monitor both of these patient populations’ heart health remotely, powered by state-of-the-art artificial intelligence (AI). This provides four key benefits:
- Provides clean, single-use devices for each patient
- Reduces patient and staff exposure by eliminating office visits
- Eliminates need for staff to clean reusable monitors that may carry the COVID-19 virus for up to 2 to 3 days
- Ensures patients continue to receive access to necessary cardiac monitoring
“COVID-19 has demonstrated clinicians’ clear need for help, both on the frontlines and in remotely caring for patients from the safety of their own homes. iRhythm is focusing 100% on helping clinicians care for patients during this pandemic by providing the Zio platform to patients that need monitoring both at home and in hospitals,” said
iRhythm will be hosting clinical education webinars for other clinicians looking to learn and leverage best practices in pivoting their practice to a virtual care model. Register for iRhythm’s webinar featuring Montefiore’s Dr.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
iRhythm Media Contact
iRhythm Investor Relations Contact